AstraZeneca's global oncology business Dato-DXd and lung cancer business unit head Lai Minglong has decided to leave

2025-06-15 19:42:40

Reporters learned that Lai Minglong, head of AstraZeneca's global oncology business Dato-DXd and lung cancer business unit, has decided to resign and seek external development opportunities. His last working day will be June 30. AstraZeneca told reporters that the news is true. Public information shows that Lai Minglong joined AstraZeneca in June 2017 and became vice president of AstraZeneca's cardiovascular and metabolic business unit in China. He was promoted to general manager of AstraZeneca China in 2018.

AstraZeneca

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Air India flight returns after takeoff due to technical issues
                            2025-06-16

                                    Southbound funds made a large net purchase of 5.743 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), China Construction Bank and Meituan-W received net purchases of HK$1.108 billion and HK$493 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$1.489 billion; in terms of Hong Kong Stock Connect (Shenzhen), Meituan-W and Kangfang Biopharma received net purchases of HK$622 million and HK$206 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$391 million.
                            2025-06-16

                                    Arm (ARM.O): We are better than Nvidia on a wider range of platforms.
                            2025-06-12

                                    Lei Jun: Xiaomi Yu7 will be released at the end of June
                            2025-06-16

                                    Putin: Russia will create unmanned system forces as a separate branch of the military
                            2025-06-13